Boehringer Ingelheim reports on Ph III adalimumab switching study

Apr 23, 2021

Boehringer Ingelheim announced results from a Ph III switching study of Cyltezo® (biosimilar adalimumab) with Humira® produced similar clinical outcomes in terms of pharmacokinetics, efficacy, immunogenicity and safety.

Print Page Mail Article